

Figure S1. *Yy1* was a potential target of miR-192-5p and miR-192-5p inhibited hepatic triglyceride synthesis by regulating the YY1/FASN pathway. (A and B) Protein levels of YY1 and FASN in MPH and HepG2 cells treated with miR-192-5p mimics (A) or inhibitors (B) revealed by Western blotting. (C and D) Protein levels of YY1 and FASN in MPH and HepG2 cells treated with miR-192-5p inhibitors (C) or miR-192-5p mimics (D) and incubated with 0.4 mM FFA for 72 h.




Figure S2. YY1 expression was upregulated in the liver of NAFLD mice, ** $p < 0.01$.

Table S1. Primers for qRT-PCR

Gene	Forward primer (5'-3')	Reverse primer (5'-3')
Mouse β -Actin	TATCGCTGCGCTGGTCGTC	CCACGATGGAGGGGAATACAG
Mouse Srebf1	GGAGCCATGGATTGCACATT	GGCCCGGGAAGTCACTGT
Mouse Acc1	GGAGATGTACGCTGACCGAG	TACCCGACGCATGGTTTTCA
Mouse Fasn	GGCCCCTCTGTTAATTGGCT	GGATCTCAGGGTTGGGGTTG
Mouse Scd1	CCTCCGGAAATGAACGAGAGA	CTGATAGGTGGGGTCGTGAA
Mouse Yy1	TGCCCTCATAAAGGCTGCAC	CTCTCAACGAACGCTTTGCC
Human β -ACTIN	GGGAAATCGTGCGTGACATT	GGAACCGCTCATTGCCAAT
Human SREBF1	ACAGTGACTTCCCTGGCCTAT	GCATGGACGGGTACATCTTCAA
Human ACC1	CACCAGTTTTGCATTGAGAAC	TACGCTGTTGAGTTCATAGGC
Human FASN	TATGAAGCCATCGTGGACGG	GAAGAAGGAGAGCCGTTGG
Human YY1	GACACCCTCTACATCGCCAC	TGTGGTCTCGATGGTCTCCA